← back to search

Tom Luedde

Heinrich Heine University Düsseldorf · DE
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver physiology and pathology, MicroRNA in disease regulation, and Cholangiocarcinoma and Gallbladder Cancer Studies.
h-index
87
citations
40,138
works
712
NIH funding
primary concept
Medicine
email

Recent publications

Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Nature Reviews Gastroenterology & Hepatology 2025cited by 30position: middledoi
The barriers to uptake of artificial intelligence in hepatology and how to overcome them
Journal of Hepatology 2025cited by 15position: middledoi
Emergence and spread of the SARS-CoV-2 omicron (BA.1) variant across Africa: an observational study
The Lancet Global Health 2025cited by 11position: middledoi
Enteronephrohepatic circulation of bile acids and therapeutic potential of systemic bile acid transporter inhibitors
Journal of Hepatology 2025cited by 10position: middledoi
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development
Nature Communications 2025cited by 9position: lastdoi
Deep learning can predict cardiovascular events from liver imaging
JHEP Reports 2025cited by 6position: middledoi
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
Cancers 2025cited by 4position: middledoi
Ferroptosis in health and disease
Redox Biology 2024cited by 283position: middledoi
Definition of the Post-COVID syndrome using a symptom-based Post-COVID score in a prospective, multi-center, cross-sectoral cohort of the German National Pandemic Cohort Network (NAPKON)
Infection 2024cited by 12position: middledoi
HBV shows different levels of adaptation to HLA class I-associated selection pressure correlating with markers of replication
Journal of Hepatology 2024cited by 9position: middledoi
Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma
Journal of Hepatology 2024cited by 6position: lastdoi
Body Composition in Cholangiocarcinoma Affects Immune Cell Populations in the Tumor and Normal Liver Parenchyma
Journal of Clinical and Experimental Hepatology 2024cited by 1position: middledoi
Systematic assessment of COVID-19 host genetics using whole genome sequencing data
PLoS Pathogens 2024cited by 1position: middledoi
Detection of Bacterial Infections and Malaria among Blood Culture-Negative Samples of Hospitalized Febrile Patients from a Tertiary Hospital in Ethiopia
American Journal of Tropical Medicine and Hygiene 2024cited by 1position: middledoi
Sublethal necroptosis signaling promotes inflammation and liver cancer
Immunity 2023cited by 131position: lastdoi
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
Journal of Hepatology 2023cited by 91position: middledoi
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma
Nature Communications 2023cited by 74position: middledoi
Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis
Journal of Hepatology 2023cited by 48position: middledoi
Regulation of STING activity in DNA sensing by ISG15 modification
Cell Reports 2023cited by 38position: middledoi
Prediction of heart transplant rejection from routine pathology slides with self-supervised deep learning
European Heart Journal - Digital Health 2023cited by 29position: middledoi
Long-term exposure to air pollution and prevalent nonalcoholic fatty liver disease
Environmental Epidemiology 2023cited by 23position: middledoi
Hepatocytes reprogram liver macrophages involving control of TGF-β activation, influencing liver regeneration and injury
Hepatology Communications 2023cited by 11position: middledoi
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)
BMC Cancer 2023cited by 4position: middledoi
Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson Disease
Journal of Clinical Medicine 2023cited by 3position: middledoi
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma
Journal of Hepatology 2022cited by 337position: middledoi
Swarm learning for decentralized artificial intelligence in cancer histopathology
Nature Medicine 2022cited by 204position: middledoi
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Zeitschrift für Gastroenterologie 2022cited by 86position: middledoi
Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity
Journal of Hepatology 2022cited by 78position: middledoi
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
British Journal of Cancer 2022cited by 34position: middledoi
Prediction of heart transplant rejection from routine pathology slides with self-supervised Deep Learning
medRxiv 2022cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Christian Trautwein · FH Aachen25 papers (2012–2023)Frank Tacke · Charité University Medicine Berlin20 papers (2012–2023) · 17 papers (2012–2024)Jakob Nikolas Kather · Ludwig-Maximilians-Universität München12 papers (2018–2025)Christoph Roderburg · Charité - Universitätsmedizin Berlin12 papers (2012–2024)Mathias Heikenwälder · German Cancer Research Center10 papers (2016–2024) · 7 papers (2012–2023)Alexander T. Pearson · RWTH Aachen University6 papers (2019–2021)Thomas Longerich · German Cancer Research Center6 papers (2018–2024)Peter Boor · RWTH Aachen University6 papers (2019–2023)Lars Zender · Deutsche Forschungsgemeinschaft6 papers (2012–2024)Sven H. Loosen · FOM University of Applied Sciences for Economics and Management6 papers (2016–2020)Heike I. Grabsch · Maastricht University5 papers (2019–2021)Ulf P. Neumann · Friedrich-Alexander-Universität Erlangen-Nürnberg5 papers (2016–2024) · 5 papers (2016–2021)Jeremias Krause · RWTH Aachen University4 papers (2019–2021)Nikolaus Gaßler · Ernst Abbe University of Applied Sciences Jena4 papers (2012–2016)Lara R. Heij · University of Amsterdam4 papers (2019–2024)Amelie Echle · RWTH Aachen University4 papers (2019–2021)Michael Hoffmeister · Festo (Germany)4 papers (2019–2020)